Eton Pharmaceuticals Appoints Danka Radosavljevic as COO

What Happened

• Eton Pharmaceuticals, Inc. (ETON) filed a Form 8‑K (Aug 4, 2026) announcing that on July 31, 2026 it appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms. Radosavljevic has been with the company since 2017 and served as Executive Vice President, Operations for more than five years, overseeing quality, product development, regulatory, supply chain and information systems.

Key Details

• Appointment effective: July 31, 2026 (reported on Form 8‑K filed Aug 4, 2026).
• Prior role: Executive Vice President, Operations at Eton (with the company since 2017).
• Compensation: annual base salary of $520,800 and an annual discretionary incentive bonus with a target of 50% of base salary (target bonus ≈ $260,400), based on corporate/individual performance targets set by the Board.
• Item reported under SEC Form 8‑K: Item 5.02 (departure/election of officers or directors).

Why It Matters

• This is a material executive leadership change: appointing an internal executive with long tenure may affect operational continuity across quality, regulatory and supply-chain functions—areas important to drug development and product delivery.
• Investors should note the compensation package and that performance-based incentives are tied to Board-approved targets; any future disclosures about those targets or related performance metrics could be relevant to assessing management priorities and company costs.